XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2021

Dec. 31, 2020

Revenues

$ 54,696

$ 34,172

$ 125,456

$ 95,973

Consumables [Member] | Transferred at Point in Time [Member]

Revenues

28,331

15,382

63,830

43,129

Hardware and Software [Member] | Transferred at Point in Time [Member]

Revenues

16,542

12,052

37,446

33,033

Service [Member] | Transferred at Point in Time [Member]

Revenues

5,446

3,780

13,288

11,548

Services and Software [Member] | Transferred over Time [Member]

Revenues

4,377

2,958

10,892

8,263

Operating Segments [Member]

Revenues

^[1]

54,696

34,172

125,456

95,973

Sterilization and Disinfection Control [Member] | Operating Segments [Member]

Revenues

^[1]

13,831

13,077

43,014

37,696

Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]

Revenues

11,718

11,250

36,579

32,252

Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]

Revenues

250

151

495

388

Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]

Revenues

392

433

1,586

1,389

Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]

Revenues

1,471

1,243

4,354

3,667

Biopharmaceutical Development [Member] | Operating Segments [Member]

Revenues

^[1]

12,756

8,711

32,188

23,791

Biopharmaceutical Development [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]

Revenues

5,503

3,406

14,329

8,583

Biopharmaceutical Development [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]

Revenues

4,907

3,771

11,936

10,518

Biopharmaceutical Development [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]

Revenues

1,297

506

2,729

2,293

Biopharmaceutical Development [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]

Revenues

1,049

1,028

3,194

2,397

Calibration Solutions [Member] | Operating Segments [Member]

Revenues

11,624

12,384

33,769

34,486

Calibration Solutions [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]

Revenues

889

726

2,701

2,294

Calibration Solutions [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]

Revenues

6,978

8,130

20,608

22,127

Calibration Solutions [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]

Revenues

2,826

2,841

8,042

7,866

Calibration Solutions [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]

Revenues

931

687

2,418

2,199

Clinical Genomics [Member] | Operating Segments [Member]

Revenues

^[2]

16,485

0

16,485

0

Clinical Genomics [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]

Revenues

^[2]

10,221

0

10,221

0

Clinical Genomics [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]

Revenues

^[2]

4,407

0

4,407

0

Clinical Genomics [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]

Revenues

^[2]

931

0

931

0

Clinical Genomics [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]

Revenues

^[2]

$ 926

$ 0

$ 926

$ 0

[1]	Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2]	Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=mlab_ConsumablesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mlab_HardwareAndSoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mlab_ServicesAndSoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_SterilizationAndDisinfectionControlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_BiopharmaceuticalDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_CalibrationSolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=mlab_ClinicalGenomicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: